Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 878 results for "mylan"

Teva pays $40.5 bn for Allergan's generics arm, dumping Mylan
Business Standard

Teva pays $40.5 bn for Allergan's generics arm, dumping Mylan

Teva will pay $33.75 billion in cash and $6.75 billion worth of shares Bloomberg July 28, 2015 Last Updated at 00:20 IST Israeli drugmaker Teva Pharmaceuticals Industries Ltd agreed to buy the generic drug business of Allergan Plc for about $40.5 billion in ... Business Standard, 6 hours ago
Teva Ends Hostile Bid for Mylan Bloomberg, 6 hours ago

756 images for mylan

Fidelity Brokerage Services LLC, 36 minutes ago
Ticker Report, 10 hours ago
Pittsburgh Post-Gazette, 3 days ago
Benefits Canada, 8 hours ago
Globes, 11 hours ago
Octafinance, 8 hours ago
CBC, 8 hours ago
Bayou Buzz, 6 hours ago
Pharma Letter, 3 hours ago
Bayou Buzz, 13 hours ago

Mylan independence from Teva's embrace comes with a price

Generic drugmaker Mylan NV won a reprieve on Monday from its unwanted suitor, Teva Pharmaceutical Industries, but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger. Teva announced a $40.5 billion deal for ...
 Reuters3 hours ago

Mylan's Leverage to Resist Teva Deal Reveals Shift in Rules

By Shayndi Raice And Liz Hoffman In May, Mylan NV's executive team met with investors in a Manhattan conference room. As shareholders complained about the drug maker's resistance to a $40 billion takeover proposal from Teva Pharmaceutical ...
 4 Traders4 hours ago

India clears foreign investment proposals of GSK, Novartis, Mylan

India has cleared a host of foreign investment proposals including Glaxo SmithKline, Novartis, Mylan, Catholic Syrian Bank and Bandhan Financial Services.
 Economic Times2 weeks ago
Business Standard

Cipla declines on negative outlook from a foreign brokerage

Cipla fell 1.57% to Rs 604.40 at 10:24 IST on BSE on reports a foreign brokerage said that launch of asthma drug by Mylan in the UK is negative for Cipla because Cipla was earlier expected to be the first company to launch this drug. Meanwhile, the S BSE ...
 Business Standard1 month ago Mylan's Asthma drug launch in UK negative for Cipla: BoAML  Money Control1 month ago Cipla drops on Mylan's asthma drug launch  Business Standard1 month ago Mylan launches anti-hepatitis drug in India  Business Standard2 months ago

Mylan recalls Bangalore unit cancer drug

US co recalling two drugs manufactured by Agila Onco, which it bought from Strides Arcolab two years back
 DNA1 month ago
India Infoline

Cipla loses 3% as Mylan launches generic Seretide

By ECONOMICTIMES.COM | 9 Jun, 2015, 01.43PM IST Post a Comment MUMBAI - Shares of Cipla fell nearly 3 per cent intraday after rival company Mylan launched first generic version of Glaxo SmithKline's anti-asthma drug Seretide in the UK market. This is seen as ...
 Economic Times1 month ago Cipla drops as Mylan launches asthma drug  India Infoline1 month ago Cipla slips as rival Mylan launches generic Seretide in UK's $400-mn anti-asthma drug market  Economic Times1 month ago
Money Control

Mylan launches hepatitis-C Sovaldi tablets in India

HYDERABAD: Pharma giant Mylan NV today said its subsidiary Mylan Pharmaceuticals has launched Gilead Sciences' Sovaldi (sofosbuvir 400mg tablets) in the country. Sovaldi is used for the treatment of chronic hepatitis-C infection as a component of a ...
 Economic Times2 months ago Mylan launches Sovaldi tablets in India  Business Standard2 months ago

Mylan, Teva push on despite rejections from Perrigo

Israel's generics giant Teva restated its interest in buying Mylan despite a blistering rejection from Mylan earlier this week. NEW YORK: Suitors in the generic drug industry's big consolidation push signaled Wednesday they would keep fighting for deals, even ...
 Economic Times2 months ago Big pharma deals: Mylan raises bid for Perrigo to $35.6 billion  Economic Times2 months ago Big deals: Mylan, Teva push on despite rejections  Economic Times2 months ago Big pharma deals: Mylan, Teva push on despite rejections  Economic Times2 months ago
Business Standard

Biocon begins phase-3 trials for cancer drug

io-technology major Biocon today said that it has made clinical progress in its partnered programmes with Mylan, a British pharma major. The partnership has a portfolio of generic insulin analogs and biosimilars including monoclonal antibodies (MAbs) and ...
 Business Standard2 months ago Biocon-Mylan Programs Make Progress: 'PEG-G-CSF and Adalimumab Enter Phase 3 clinical trials' and 'Patient Recruitment for One Insulin Glargine Phase 3 Study is Completed'  Andhra News2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - mylan
Get updated on latest news & your favorite topics right in your inbox!
More     Less